All News
Filter News
Found 3,892 articles
-
Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer
11/2/2023
Endeavor BioMedicines, a clinical-stage company developing therapies for of fibrotic disease and oncology, announced the appointment of Paul Frohna, M.D., Ph.D., as its Chief Medical Officer.
-
Vincerx Pharma To Present Three Posters at ASH 2023 in December
11/2/2023
Vincerx Pharma, Inc. announced that it will present three posters related to VIP943, VIP924, and enitociclib at the 65th American Society for Hematology Meeting, taking place in San Diego California from December 9 to 12, 2023.
-
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
11/2/2023
ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023.
-
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
11/2/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2023 financial results and corporate highlights.
-
The regulator has released Mersana Therapeutics’ antibody-drug conjugate XMT-2056 from its clinical hold, allowing the biotech to proceed with Phase I studies of the candidate with a lower starting dose.
-
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
11/1/2023
Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer.
-
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
11/1/2023
Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023.
-
CytomX Therapeutics to Present at Upcoming November 2023 Investor Conferences
11/1/2023
CytomX Therapeutics, Inc., a leader in the field of conditionally activated, localized biologics, announced that management will participate in the following investor conferences in November.
-
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
11/1/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the third quarter ended September 30, 2023.
-
ALX Oncology Announces November 2023 Investor Conference Participation
11/1/2023
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that management will participate in three upcoming investor conferences in November.
-
Zymeworks Announces Participation in Upcoming Investor Conferences - November 1, 2023
11/1/2023
Zymeworks Inc. today announced that management will participate in the following upcoming investor conferences.
-
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
11/1/2023
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2023 operating and financial results webcast on Wednesday, November 8, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.
-
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
11/1/2023
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today provides strategic pipeline updates and reports third quarter financial results.
-
BostonGene to Present Research with Leading Cancer Centers at Society for Immunotherapy of Cancer’s 2023 Annual Meeting
11/1/2023
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 at the San Diego Convention Center in San Diego, CA.
-
CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023
10/31/2023
CytomX Therapeutics, Inc. today announced that it will report third quarter financial results on Tuesday, November 7, 2023, after the close of U.S. markets.
-
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
10/31/2023
Mersana Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company’s Phase 1 clinical trial of XMT-2056.
-
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
10/31/2023
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023.
-
Hengrui Pharma Partners with Merck KGaA, Darmstadt, Germany, to Advance Innovative Cancer Therapies
10/30/2023
Jiangsu Hengrui Pharmaceuticals Co., Ltd announced a licensing agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, for its next-generation potent and selective PARP1 inhibitor, HRS-1167.
-
SparX Biopharmaceutical Announces FDA Greenlight for IND Application of SPX-303, A First-In-Human anti-LILRB2/PD-L1 Antibody Drug
10/30/2023
Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug (IND) application for SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate, has been greenlighted by the U.S. Food and Drug Administration (FDA).
-
Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
10/30/2023
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd.